Dong Mei, Wang Rujian, Sun Ping, Zhang Dongxia, Zhang Zhenzhen, Zhang Jing, Tse Gary, Zhong Lin
Department of Cardiology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China.
Department of Oncology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong 264000, P.R. China.
Oncol Lett. 2021 Apr;21(4):315. doi: 10.3892/ol.2021.12576. Epub 2021 Feb 23.
Hypertension is a common comorbidity in patients receiving antiangiogenic therapy. Prior studies have reported worsening or new-onset hypertension as an adverse event of antiangiogenetic therapy, which can be managed by dose reduction or discontinuation of the culprit medication. By contrast, other studies have found that the occurrence of hypertension is a potential biomarker associated with greater efficacy of antiangiogenic therapy and predicts improved survival. At present, there is no consensus on the effects of hypertension in patients treated with antiangiogenic drugs. The present study reviewed the relationship between antiangiogenic drugs and hypertension in different types of cancer. It was demonstrated that the use of antiangiogenic drugs was associated with an increased risk of hypertension in most types of solid cancers. There was no significant difference in the incidence of hypertension between monoclonal antibody and small-molecule tyrosine kinase inhibitor treatments. Hypertension was more likely to occur in patients younger than 75 years old, female, and those with no history of bevacizumab use. Discontinuation or death caused by hypertension was rare, although previous studies have reported that hypertension was a risk factor for acute and chronic cardiovascular diseases and ischemic stroke. Of note, the early development of hypertension may serve as a potential biomarker associated with greater efficacy of antiangiogenic therapy.
高血压是接受抗血管生成治疗患者的常见合并症。既往研究报道，高血压病情恶化或新发高血压是抗血管生成治疗的不良事件，可通过减少剂量或停用相关药物来处理。相比之下，其他研究发现高血压的发生是一种与抗血管生成治疗疗效增强相关的潜在生物标志物，并预示生存期改善。目前，对于接受抗血管生成药物治疗的患者，高血压所产生的影响尚无定论。本研究回顾了不同类型癌症中抗血管生成药物与高血压之间的关系。结果表明，在大多数实体癌类型中，使用抗血管生成药物与高血压风险增加相关。单克隆抗体治疗和小分子酪氨酸激酶抑制剂治疗的高血压发生率无显著差异。高血压更易发生于75岁以下的患者、女性以及未使用过贝伐单抗的患者。尽管既往研究报道高血压是急性和慢性心血管疾病及缺血性卒中的危险因素，但因高血压导致的停药或死亡情况罕见。值得注意的是，高血压的早期出现可能是一种与抗血管生成治疗疗效增强相关的潜在生物标志物。
